In a study of more than 25,000 people — with nearly all of them vaccinated and 95 percent received three or more COVID-19 vaccine shots — comparing Lagevrio to usual care, the primary endpoint of reducing hospitalizations and deaths within 28 days was not met.
A separate Lagevrio study of 13,569 people, researchers found a lower rate of hospitalizations and deaths among patients 65 and older, but not among younger adults, according to Merck.
Recent data on other COVID-19 treatments also show a slowing of efficacy.
The only COVID-19 preexposure prophylaxis treatment with emergency use authorization, AstraZeneca’s Evusheld, may not be as effective against new variants, the FDA said Oct. 3. In mid-September, the World Health Organization placed GSK’s treatment sotrovimab and Regeneron’s drugs, casirivimab and imdevimab, in its “strong recommendations against” tier.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
